Suchergebnisse - "Akimoto, Kazumi"

PubPharm (91)

1

Clinical significance of increased levels of endogenous Muse cells in the myocardium of patients with fulminant myocarditis

enthalten in: ResearchSquare.com | 2024

von Toyoda, S. | Sakuma, M. | Ishida, K. | +6

2

Complete Thrombotic Occlusion of the Abdominal Aorta

enthalten in: Internal medicine (Tokyo, Japan) | 2022

von Kamano, S. | Morimoto, Y. | Akimoto, K. | +1

3

A case of hypoparathyroidism, deafness, and renal dysplasia (HDR) syndrome with a novel frameshift variant in GATA3, p.W10Cfs40, lacks kidney malformation

enthalten in: Clinical case reports | 2020

von Kishi, H. | Jojima, T. | Kogai, T. | +13

4

Genetic alteration of ARMC5 in a patient diagnosed with meningioma and primary macronodular adrenal hyperplasia : a case report

enthalten in: European journal of endocrinology | 2020

von Jojima, T. | Kogai, T. | Iijima, T. | +13

5

A case of hypoparathyroidism, deafness, and renal dysplasia (HDR) syndrome with a novel frameshift variant in GATA3, p.W10Cfs40, lacks kidney malformation

enthalten in: Clinical Case Reports | 2020

von Kishi, H. | Jojima, T. | Kogai, T. | +13

6

Cancer-associated fibroblasts show heterogeneous gene expression and induce vascular endothelial growth factor A (VEGFA) in response to environmental stimuli

enthalten in: Annals of gastroenterological surgery | 2019

von Inoue, K. | Kishimoto, S. | Akimoto, K. | +6

7

Liraglutide, a GLP-1 receptor agonist, inhibits vascular smooth muscle cell proliferation by enhancing AMP-activated protein kinase and cell cycle regulation, and delays atherosclerosis in ApoE deficient mice

enthalten in: Atherosclerosis | 2017

von Jojima, T. | Uchida, K. | Akimoto, K. | +6

8

Dual pharmacological inhibition of glutathione and thioredoxin systems synergizes to kill colorectal carcinoma stem cells

enthalten in: Cancer medicine | 2016

von Tanaka, G. | Inoue, K. | Shimizu, T. | +2

9

Empagliflozin (an SGLT2 inhibitor), alone or in combination with linagliptin (a DPP-4 inhibitor), prevents steatohepatitis in a novel mouse model of non-alcoholic steatohepatitis and diabetes

enthalten in: Diabetology & metabolic syndrome | 2016

von Jojima, T. | Tomotsune, T. | Iijima, T. | +3

10

Empagliflozin (an SGLT2 inhibitor), alone or in combination with linagliptin (a DPP-4 inhibitor), prevents steatohepatitis in a novel mouse model of non-alcoholic steatohepatitis and diabetes

enthalten in: Diabetology & metabolic syndrome | 2016

von Jojima, T. | Tomotsune, T. | Iijima, T. | +3

1
2
3
4
5
6
7
8
9
10
Nächster »
[10]